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The knowledge base of nutrition and the brain is steadily expanding. Much of the research is aimed at
ways to protect the brain from damage. In adults, the major causes of brain damage are aging and
dementia. The most prominent dementia, and the condition that grabs the most public attention, is
Alzheimer’s disease. The assumption in the ﬁeld is that possibly some change in nutrition could protect
the brain and prevent, delay, or minimize Alzheimer’s disease damage. Presented here is a framework for
understanding the implications of this research. There is a gap between publishing research results and
change in public nutrition behavior. Several inﬂuencing elements intervene. These include regulatory
agencies and all the organizations and people who advise the public, all with their own perspectives. In
considering what advice to give, advisors may consider effectiveness, research model, persuasiveness, and
risks, among other factors. Advice about nutrition and Alzheimer’s disease today requires several caveats.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Many studies have shown an association of nutrition and the
brain (Bowman et al., 2012). A number of important studies are
included in this issue. Unquestionably, the universe of new infor-
mation is rapidly growing. What is the signiﬁcance of all these new
data? When contemplating new ﬁndings, it is useful to step back
and look at the environment in which they will be used. The
assumedmodel is that research results could lead tomodiﬁcation of
nutritional intake that could protect the brain from damage;
therefore, a change in public nutrition would be useful. One of the
most prevalent conditions causing brain damage is dementia, and
Alzheimer’s disease is the most common dementia. That Alz-
heimer’s disease could be reduced by nutritional modiﬁcation is of
great interest to the public and public health agencies, and has
produced a large market.
Although the end users of nutrition research would be the
public, there are important modiﬁers before wide public impact
might be achieved (Table 1). In a typical research project, a
researcher designs a study, obtains support, performs the research,
and publishes the ﬁndings, making them available to the public.
There is a gap between the public’s access to the research ﬁndings
and any change in nutritional behavior. This gap sets the framework
for understanding the implications of the research. Intermediaries
in the gap include marketers of products, agencies that regulateine/Geriatrics and Palliative
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Y-NC-ND license.health products, and those who directly advise individuals, such
as clinicians and other health-care providers, organizations, and
media. This review discusses the perspectives of those in the gap
between research results and change in public nutrition behavior,
that is, marketers, agencies, and advisers.2. Deﬁnitions and background
“Nutrition” is deﬁned as “the science of food ... in relation to
health and disease” (National Agricultural Library, 1998). “Food” is
not speciﬁcally deﬁned by US agencies. In general, it is a substance
that enters the stomach, provides energy, and/or sustains normal
metabolism. Minimum daily requirements of food categories
(proteins, elements, and vitamins), now called Dietary Reference
Intake amounts, have been established (Food and Nutrition Board,
2010). In the United States, claims for health beneﬁts from foods
are regulated by the Food and Drug Administration (FDA) if the
claim is for disease prevention or treatment and otherwise by the
Federal Trade Commission (FTC) (FDA, 2013).
“Dietary supplements” are considered to be food by the FDA
(Government Printing Ofﬁce, 2010). They contain “’dietary in-
gredients’ like vitamins, minerals, herbs or other botanicals, amino
acids, and enzymes.” They are subject to food safety requirements
and cannot make claims to prevent or cure any disease. A product
that is claimed to prevent or cure a disease is a “drug” and must
show efﬁcacy and be approved by the FDA in the United States.
Other claims that supplement marketers make, such as “May sup-
port brain health,” might be allowed, but are subject to approval by
the FDA, and must be based on acceptable scientiﬁc evidence.
Table 1
Typical trail from researcher to change in public nutrition behavior
Researcher Initiates and develops project
Sponsor Fund researcher
Researcher Performs research, preliminary, intermediary, or
randomized trial
Public platform Displays results in journal, Web site, and conference
Vendor (sometimes) Markets product
FDA Monitors if claims are made for disease prevention
or treatment
FTC Monitors claims if they are not under jurisdiction of
FDA and have interstate commerce implications
Advisory groups Some independent, some commercially funded,
they make and state positions. They include the
Centers for Disease Control and the US Department
of Agriculture
Personal advisors Clinicians, journalists, other media, either push
recommendations or are pulled to do so.
Recommendations can be negative
Insurers Decide if the change is covered
Public Accepts or ignores recommendations and changes
behavior or not
Key: FDA, Food and Drug Administration; FTC, Federal Trade Commission.
Table 2
Possible primary etiologic mechanisms for Alzheimer’s diseasea
 Imbalance in brain beta-amyloid production vs. destruction
(Wildsmith et al., 2013)
 Toxic fragments of beta-amyloid precursor protein (Hartmann, 1999)
 Abnormal phosphorylation of tau (Dugger et al., 2013)
 Inﬂammation/oxidation (Grifﬁn, 2013)
 Insulin resistance (Craft et al., 2013)
 Infection (herpes, cytomegalovirus, others) (Carbone et al., 2013)
 Vascular disease: poor blood perfusion (Zlokovic, 2011)
 Vascular disease: strokes, silent strokes, and accumulation of ischemic
damage (Lo and Jagust, 2012)
 Vascular disease: endovascular malfunction in blood brain barrier
(Zlokovic, 2011)
a Nine possible primary etiologies for Alzheimer’s disease as discussed at a
national meeting to focus research funding (National Institute of Neurological
Disorders and Stroke, 2013). Deﬁciency of acetylcholine, a brain neurochemical, is
often cited as etiologic for Alzheimer’s disease but must be secondary to some
underlying causation.
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misleading or exaggerated claims (FTC, 2013).
“Medical foods” are a relatively new category. Originally inten-
ded to refer to enteral (tube) feeding substances, medical foods
must be administered under the direction of a licensed clinician but
do not need FDA approval. As with supplements, medical food
vendors cannot claim disease prevention or treatment value, and
the FTC can control advertising claims.
“Dementia” is a category of progressive degenerative brain
disorders. The most commonly discussed dementia is Alzheimer’s
disease. The cause of Alzheimer’s disease is unknown. Much is
known about its changes in the brain, but there are competing
hypotheses about the primary driving mechanism. At a recent
international meeting to help formulate research, at least 9
abnormalities were listed as possible primary etiologies (Table 2)
(National Institute of Neurological Disorders and Stroke, 2013). If
any of these is primary (as opposed to being the result of another
cause), then changes in nutrition would need to overcome the
speciﬁc abnormality to be useful.
To the public and most clinicians, Alzheimer’s disease occurs
when a set of clinical signs appear and other conditions are
excluded, and this usually happens later in life. However, when a
clinical diagnosis of Alzheimer’s disease is made, it is now consid-
ered Stage 3 disease. Stage 2 disease is mild cognitive impairment
because of Alzheimer’s disease. (Note that this is a special kind
of mild cognitive impairment and can only be attributed to
Alzheimer’s disease by special tests not widely available. Deﬁni-
tions are not fully standardized.) Stage 1 Alzheimer’s disease occurs
years earlier, when the disease process has started, but there are no
or limited symptoms (Jack et al., 2011).
Although themost prevalent dementia is commonly understood
to be Alzheimer’s disease, the role of vascular disease in Alzheimer’s
disease is so prominent that many consider the most prevalent
dementia to be “mixed dementia,” with both amyloid plaques
deﬁning Alzheimer’s disease and signiﬁcant vascular disease injury.
No medication or medical intervention has been shown to
prevent or modify the course of Alzheimer’s disease. Some medi-
cationsmay improve symptoms. These are cholinesterase inhibitors
(donepezil, galantamine, and rivastigmine) and an N-methyl-D-
aspartate receptor antagonist (memantine). Many specialists
emphasize the value of behavioral therapy, in which caregivers are
encouraged to modify their expectations and the patient’s
environment.3. Public impact
The public burden of Alzheimer’s disease is immense. The cost of
care now equals or is greater than the cost of care for heart disease
or cancer (Hurd et al., 2013). A recent estimate of cost of care in the
US for Alzheimer’s patients was $159e$215 billion a year (Assistant
Secretary for Planning and Evaluation, 2013). The strongest risk
factor for Alzheimer’s disease is age. One of 3 older people will die
from or with dementia. Because deaths from other diseases such as
certain cancers and heart disease have declined in the United States,
more people are surviving into the age range of higher Alzheimer’s
disease incidence; so, the prevalence of Alzheimer’s disease has
increased. As large population cohorts such as the “Baby Boomers”
enter old age, the burden, both dollar cost and personal/family
suffering, will continue to increase.
Good news is that the age-speciﬁc incidence may be decreasing
(Matthews et al., 2013; Rocca et al., 2011). This means that, although
there may be more people in the high-risk age pool and thus more
cases overall, for any speciﬁc age, the rate of new cases may be
lower. Because there is no known medical intervention to prevent
Alzheimer’s disease, the effect may be from improved environment
or lifestyle. One speculated lifestyle improvement is better
nutrition.
4. Public demand
Over half of adult Americans take some sort of dietary supple-
ment, spending more than $20 billion annually, an amount
increasing yearly (DaVanzo et al., 2009; Gahche et al., 2011). This
market is understandable, as diseases like Alzheimer’s are dreaded,
and claims that certain foods and supplements may reduce the risk
are strongly appealing. A challenge for providers and other advisors
is deciding what to tell individuals about their nutrition and the
brain.
5. Advice from national agencies
If a modiﬁcation in nutrition, either a speciﬁc diet or a supple-
ment, can improve public health, and an agency is persuaded that
the modiﬁcation provides an overall public beneﬁt, the agency
could encourage the public to follow the modiﬁed diet, just as
clinicians may encourage individuals. The Centers for Disease
Control and Prevention (CDC), for instance, has found the Dietary
Approaches to Stop Hypertension (DASH) diet effective to reduce
cardiovascular risk; so, the CDC recommends it to the public, stating
“to reduce your risk of heart disease and strokedfollow the DASH
eating plan” (CDC, 2013).
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nutrition and the brain, so far no diet or dietary supplement has
been proved to be effective to reduce the risk of Alzheimer’s dis-
ease. The National Institutes of Health convened a group of experts
in 2010. The panel reviewed available evidence and concluded that
“currently, no evidence of even moderate scientiﬁc quality exists to
support the association of any modiﬁable factor (such as nutritional
supplements, herbal preparations, dietary factors, prescription or
nonprescription drugs, social or economic factors, medical condi-
tions, toxins, or environmental exposures) with reduced risk for
Alzheimer disease” (Daviglus et al., 2010). Consistent with this
conclusion, no agency in the United States recommends a diet or
supplement to reduce the risk of Alzheimer’s disease.
On the other hand, agencies do recommend generally a healthy
diet. The National Institute on Aging suggests that “a healthy eating
pattern” could be either the DASH diet or the Dietary Guidelines for
Americans from the Department of Agriculture (National Institute
on Aging, 2013a). Whereas agencies and organizations such as the
Alzheimer’s Association often recommend a healthy diet, none
recommend a speciﬁc diet or speciﬁc food or supplement to pre-
vent Alzheimer’s disease.
Yet, the public sees research results that suggest dementia risk
can be reduced and with hopeful curiosity seeks advice from
trusted sources. The rest of this discussion focuses on factors that
may affect the perspective of those who must provide advice in the
current environment of uncertainty.
6. Perspectives of groups in the gap
The perspective of marketers is simple enough: is the product
safe? Could it be proﬁtable? The perspective of agencies is generally
the same as health-care providers.
6.1. Effectiveness
The key concern of agencies and providers is whether a pro-
posed change is effective. In this sense, “effective” has a special
meaning. A change is effective only if the outcome is a meaningful
beneﬁt in a human population in “real-life” circumstances
(Gartlehner et al., 2006). “Beneﬁt” is net beneﬁt and must include
consideration of costs. “Costs” include morbidity, mortality, and
economic cost. This is a simpliﬁed description of effectiveness. The
subject can be complex.
For example, a controversial outcome is the “surrogate beneﬁt.”
If a nutritional intervention causes a surrogate beneﬁt such as an
improvement in a blood level or a positron emission tomography
scan, is that a real beneﬁt? Or must it also need to show a mean-
ingful improvement in some function or symptom? As an illustra-
tion, a recent study examined the effects of antioxidant nutritional
supplements on the brain (Galasko et al., 2012). Subjects received a
combination of vitamin C, alpha-lipoic acid, and vitamin E as alpha-
tocopherol. These antioxidants are often suggested as useful to
prevent brain damage. Measures included cerebral spinal ﬂuid
analysis and brain function testing. The antioxidants did produce a
reduction in oxidation products (a surrogate beneﬁt). However,
with respect to function, subjects receiving antioxidants had
“accelerated decline in (brain function), a potential safety concern”
(Galasko et al., 2012). Although the surrogate beneﬁt might have
encouraged advice to take these antioxidants, the functional results
suggested that the supplements, instead of beneﬁcial, might actu-
ally be harmful. Deﬁning acceptable outcome measures vexes all
aspects of Alzheimer-related research. One goal of the US National
Alzheimer’s Project is to “develop standard outcome measures to
enable data comparisons across studies. These include but are not
limited to ecologically valid measures of real world function, qualityof life, and physical and cognitive function” (National Institute on
Aging, 2013b).
6.2. Persuasiveness
A critical consideration in the path of a nutritional research
ﬁnding to its implementation is how “persuasive” is the argument
for change? This is affected by societal value judgments and
priorities, among other factors. An important part of persuasiveness
is the concept of meaningful beneﬁt. Even when an outcome is a
beneﬁcial functional beneﬁt (shows effectiveness), it is not neces-
sarily a clinically meaningful beneﬁt. Small effect sizes may be
statistically signiﬁcant but might not reﬂect a gain that is mean-
ingful to the public. This determination is subjective, but can
override statistically signiﬁcant results, and represents an issue
across health-care research (Keefe et al., 2013). Another important
factor in persuasiveness is the research model that was used.
7. Nutrition research models: strengths and weaknesses
Many believe that reducing cardiovascular disease will reduce
the risk of Alzheimer’s disease. Therefore, it was of interest when in
spring 2013, news sources announced that a new study that
showed high blood levels of plasma phospholipid omega-3 fatty
acids seemed to protect against cardiovascular disease and death
(Mozaffarian et al., 2013). The study was population based in which
subjects in the highest quintile of plasma phospholipid omega-3
fatty acid range were compared with those in the lowest quintile.
The implication was that omega-3 fatty acids were protective, and
the news encouraged advice to people to increase their omega-3
fatty acid intake. Of course, the easiest way to do that is to take a
supplement.
A few weeks later, a randomized controlled trial (RCT) showed
that taking omega-3 fatty acid supplements did not protect against
cardiovascular disease and death (Roncaglioni et al., 2013). As an
RCT, the persuasive impact of this research is much stronger than a
population study. Advice to take omega-3 fatty acid supplements to
protect against cardiovascular disease now appears unwarranted.
This is a recent example of the weakness of population observation
studies, which cannot control for all variables. The lowest quintile
subjects in the population studymay have includedmorewhowere
homeless or in grave poverty and not able to obtain balanced
nutrition or health care. Observation studies are inherently less
reliable than RCTs as a basis for making recommendations.
On the other hand, RCTs have issues of their own. External
validity or generalization can be affected by subject inclusion/
exclusion criteria, the outcome selected for study, and trial dura-
tion, for example. To achieve a representative sample, RCTs usually
require cooperation of multiple sites and can be very expensive. The
logistics for an RCT to intervene in Stage 1 Alzheimer’s disease,
years before clinical signs appear, could be overwhelming.
Good non-RCT research is valuable, then, even if it is not
deﬁnitive in framing recommendations. Research can be seen as a
spectrum. One can imagine a scale with case reports and
convenience-sample observations on the left and RCTs on the right.
In between are animal, case-control, and high-grade population
studies comparing high and low in the same population. The closer
a study is to the right; themore persuasive the results are inmaking
recommendations for changes in nutritional behavior.
Non-RCT studies can develop and test hypotheses, highlight
opportunities, and provoke the need for RCTs. Additionally, obser-
vation studies can be useful for negative outcomes. Failure to ﬁnd
beneﬁt in a population observation study usually shuts off plans for
a randomized study, saving time and effort. Observation studies
sometimes are also the only way information can be found. A recent
J.K. Cooper / Neurobiology of Aging 35 (2014) S79eS83S82study showed that high levels of omega-3 fatty acids increased
the risk of prostate cancer (Brasky et al., 2013). It would now be
virtually impossible to initiate a randomized study of omega-3 fatty
acid supplements in a general population of men.
8. At least it is not harmful
It is often said about diet changes and nutritional supplements
that even if they are not beneﬁcial, at least they are not harmful.
However, there can be a direct monetary cost to diet modiﬁcation.
Supplements can cost hundreds of dollars a month. Special diets
and foods may be more expensive than routine foods; people
adhering to the DASH diet may pay
e
20% more for their food
(Bertonie, 2013). Besides monetary loss, there may be lost oppor-
tunities. People following a special diet or taking supplements they
believe will reduce their chance of dementia may be more
complacent and not participate in exercise or other activity than
could be more beneﬁcial.
Also, there can be direct morbidity associated with a nutrition
intervention. In one study, a group of men were divided into 2
groups: one group received a nutrition intervention, a low satu-
rated fat diet, and the other group was the control (Pearce and
Dayton, 1971). Men in the low saturated fat group had fewer car-
diovascular events but more cancer. Looking at deaths, in the diet
group, 31 of 174 deaths were because of cancer, whereas in the
control group, only 17 of 178 deaths were from cancer (Pearce and
Dayton, 1971). Hence, the diet intervention increased the risk of
cancer. As noted, recommendations to take omega-3 fatty acid
supplements in the past increased the risk of prostate cancer in
men who followed the recommendations. Another example is that
vitamin E had been recommended as a way to slow the progress of
Alzheimer’s disease (Sano et al., 1997). However, vitamin E not only
has no proven effectiveness but also increases the risk of cancer in
men (Nicastro and Dunn, 2013).
A recent study of older Iowa women showed that taking any
nutritional supplement was risky. This was especially true for iron:
the overall increasedmortality hazard ratio (HR) for iron takers was
10% higher than non-takers (HR 1.10 [1.03e1.17]). The longer the
women took the supplement, the higher the HR, approaching 50%
higher for some groups. The effect was dose responsivedthose
taking more iron had higher risk. Last, even the popular and
federally supported advice to limit daily salt intake may be harmful,
according to a review by the National Academies of Science
(Institute of Medicine, 2013).
9. Advice to give today
In summary, the products of nutrition research often lead to
suggestions to change diets or consume supplements to achieve
preventive or disease mitigating beneﬁts for the public. No national
agency in the United States recommends a speciﬁc change to
prevent or modify Alzheimer’s disease. Before recommending such
a change, agencies and clinicians consider the following critical
aspects of the research: the effectiveness of the change, with the
special meaning of effectiveness; the research model used; the
outcome that would be modiﬁed and the degree of relevance if it is
a surrogate outcome; if the estimated outcome effect is clinically
meaningful; and the potential for harm, both economic and in
morbidity.
So far, no nutritional intervention has been proved to be effec-
tive in reducing the risk or severity of Alzheimer’s disease or any
dementia. To be intellectually honest, recommendations to reduce
the risk or severity of Alzheimer’s disease by a speciﬁc diet or
supplement must contain a disclaimer. It must be said that there
is no sufﬁcient evidence to claim effectiveness of therecommendation, and the recommendation may in fact lead to
harm. On the other hand, it is warranted to recommend pursuing a
generally healthy diet and to provide direction to healthy diet
options (Barnard, 2014). And encouragingly, a number of large RCT
studies are underway to test the effectiveness of several nutrients,
including coconut oil, blueberries, lipoic acid, and omega-3 fatty
acids (National Institute on Aging, 2013c). More ﬁndings will
undoubtedly come as these RCTs are the natural follow-up of
intermediate research on nutrition and the brain. For agencies,
clinicians, and others who advise people, they may provide the
conﬁdence to make more ﬁrm recommendations, for or against,
speciﬁc nutrition changes to reduce or control Alzheimer’s disease.Disclosure statement
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